Navigation Links
Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
Date:10/31/2013

of revenue.

Bausch + Lomb TransactionOn August 5, 2013, Valeant completed its acquisition of Bausch + Lomb.  We expect to realize more than $850 million of cost synergies from the combined Company, with a run rate north of $500 million by year-end 2013 and a run rate more than $850 million by year-end 2014.  

2013 GuidanceThe Company is updating its 2013 Cash EPS guidance to $6.11 to $6.16.  Total revenue for 2013 is expected to be in the range of $5.7 billion to $5.9 billion and adjusted Cash Flow from Operations is expected to be greater than $1.8 billion.

Conference Call and Webcast InformationThe Company will host a conference call and a live Internet webcast along with a slide presentation today at 8:00 a.m. ET (5:00 a.m. PT), October 31, 2013 to discuss its third quarter financial results for 2013. The dial-in number to participate on this call is (877) 876-8393 confirmation code 72650802. International callers should dial (973) 200-3961, confirmation code 72650802. A replay will be available approximately two hours following the conclusion of the conference call through November 7, 2013 and can be accessed by dialing (855) 859-2056, or (404) 537-3406, confirmation code 72650802. The live webcast of the conference call may be accessed through the investor relations section of the Company's corporate website at www.valeant.com.

About ValeantValeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements This press release may contain forward-looking statements, including, but not limited to, statements regarding the amount and t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... treating MCLs nonsurgically, study findsROSEMONT, Ill., March 2 ... (MCL) may be treated successfully without surgery, according to ... of The Journal of the American Academy of ... review,s authors found, is properly diagnosing and understanding the ...
... Md., March 2 TissueGene, Inc. announced today that ... (KLS) has received regulatory allowance from the Korea Food ... clinical trial of TissueGene-C (TG-C) in patients with severe ... for the localized delivery of allogeneic human cells expressing ...
Cached Medicine Technology:Treating Knee Ligament Injuries 2Treating Knee Ligament Injuries 3TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee 2
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
(Date:4/23/2014)... whose testosterone falls below normal levels are more likely ... have heart disease and type 2 diabetes. A new ... further testing and possible treatment is described in an ... peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The ... Men,s Health website at http://www.liebertpub.com/jmh . ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... cabinet, may help in easing out prostate problem, according to ... known to help in the prevention of arthritic inflammations, heart ... The researchers say that now it may help solve some ... enlarged prostates. ,It may help reduce the urinary ...
... view of The Sterling Council, of levying ?1 a week for ... refuses to buy. The complainant, Mrs. C, has not minced words ... the society, and truly a mockery of the free care provided ... emergency care system in her home in 2002. This allowed emergency ...
... of the University of Sao Paulo Medical School in Brazil ... getting the best care in case of chronic coronary artery ... to be published in the September edition of the Journal ... to receive their physician-recommended treatment showed a significantly lower incidence ...
... A British tourist in Hong Kong is suspected of having the ... been named and was admitted to a Hog Kong hospital// after ... man came to the country on April 4 and was admitted ... Chinese origin and underwent intestinal surgery earlier. Hong Kong health department ...
... A $500,000 television and radio ad campaign blaming GOP ... prescription drug program has been launched by the// Association ... ,The ad campaign accusing the lawmakers for blocking provisions ... companies for the best prescription cost has been targeted ...
... techniques and concussions among high school athletes found that ... of// concussion. ,In the current ... Medicine in Philadelphia and co-author Dr. Tracey Covassin of ... directors of athletics from Pennsylvania and New Jersey high ...
Cached Medicine News:Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 3Health News:Ad Campaign Targeting Republicans On Medicare Prescription Drug Program 2Health News:Proper Fitting Of Football Helmets Essential To Prevent Concussion 2
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures....
The Shandon Linistain GLX Linear Stainer is an economical mid-size linear stainer featuring 28 staining stations and a heater/dryer with fume control by a charcoal filter....
... Finesse E+ is a precision ... specimen advance with manual cutting. ... is easy to operate. Coarse ... the option of manually advancing ...
Medicine Products: